|
|
Current and Breaking News for Professionals, Consumers and Media |
|
|
|
|
|
|
| Current and Breaking News for Professionals, Consumers and Media |
|
|
|
|
|
C. difficile affects several million people and is linked to 14,000 deaths per year in the United States, according to the Centers for Disease Control and Prevention. Symptoms of C. difficile infection include fever, nausea, and diarrhea, and most often occur following a prescribed course of antibiotics. The antibiotics kill normal microbes that live in the colon, thereby making the patient more susceptible to infections such as C. difficile. Paradoxically, while the cause of C. difficile infection is exposure to antibiotics, the infection itself is also treated using antibiotics, which can make things worse. C. difficile infections typically affect older adults in hospitals or in long-term care facilities, but is increasingly spreading into the wider community. In recent years it has become more frequent, more severe and more difficult to treat. Patients suffering from the infection require costly care -- researchers suggest it costs $2,500-7,000 to treat each patient suffering from C. difficile.1 “C. difficile can be suppressed with antibiotics, which have the unfortunate side effect of killing off the normal colon bacteria that offer protection against infection,” says Alexander Khoruts, M.D., co-inventor and associate professor of medicine. “Antibiotics don’t work very well because they only suppress the C. difficile. Once you remove the antibiotic, it produces more of the infection,” says Michael Sadowsky, co-inventor and McKnight University professor in the Biotechnology Institute and Department of Soil, Water, and Climate. The invention, a bacterial preparation, can enable restoration of normal bacteria in the colon. “We are very excited to be working with the University of Minnesota in commercializing a treatment that has approximately 95% efficacy,” says Geoff Rosenhain, founder of CIPAC. “Our goal is to bring to market a safe, natural and effective alternative to current treatment options, and to restore the wellbeing of patients suffering from debilitating C. difficile infections.” CIPAC is working with the FDA to begin clinical trials for the preparation. The technology was licensed exclusively to CIPAC by the university’s Office for Technology Commercialization. ### The mission of the University of Minnesota’s Office for Technology Commercialization is to translate University research into new products and services that provide growth opportunities for its licensees, benefit the public good, improve the quality of life and generate revenue to support the University's research and education goals. 1. Dubberke, Erik R.; Reske, Kimberly Ann; Olsen, Margaret A.; McDonald, Clifford; and Fraser, Victoria J., "Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients." Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 46, 4, 497-504. 2008. Paper 8. ### For advertising and promotion on HealthNewsDigest.com please contact Mike McCurdy: tvmike13@HealthNewsDigest.com or 877-634-9180 HealthNewsDigest.com is syndicated worldwide, to thousands of journalists and health-related websites. www.HealthNewsDigest.com Top of Page 
|
Contact
Us | Job Listings
| Help | Site
Map | About Us
Advertising
Information | HND
Press Release | Submit
Information | Disclaimer
Site hosted by Sanchez Productions
